Episode 6: Among the topics: The latest on Patent Foramen Ovale (PFO) closure - Spontaneous Coronary Artery Dissection (SCAD)

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Update on indications and methods for Patent Foramen Ovale (PFO) closure Incidence, outcome, acute and chronic treatment of Spontaneous Coronary Artery Dissection (SCAD) Mythbusters: The earlobe crease Host: Rick Grobbee Guests: Carlos Aguiar, Lorenz Raeber and Jacqueline Saw Want to watch that episode? Go to: https://esc365.escardio.org/event/802 Disclaimer: This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Jacqueline Saw declared to have no potential conflict of interest to report. Carlos Aguiar declared to have potential conflict of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno declared to have potential conflict of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi. Lorenz Raeber declared to have potential conflicts of interest to report: Consultation/speaker fees from Abbott, Amgen, AstraZeneca, Canon, Medtronic, Novo Nordisk, Occlutech, Sanofi. Research grants to the institution by Abbott, Biotronik, Heartflow, Sanofi, Regeneron. Emma Svennberg declared to have potential conflict of interest to report: Institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.